Citadel Advisors’s Cidara Therapeutics CDTX Stock Holding History

Citadel Advisors’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-36,800	Closed	-$8.13M	–	13086
2025 Q4	$8.13M	Sell	36,800 -49,300	-57%	-$7.97M	﹤0.01%	3530
2025 Q3	$8.24M	Buy	86,100 +28,800	+50%	+$1.84M	﹤0.01%	3554
2025 Q2	$2.79M	Buy	+57,300	New	+$1.38M	﹤0.01%	5096
2024 Q2	–	Sell	-5	Closed	-$92	–	14330
2024 Q1	$92	Buy	+5	New	+$72	﹤0.01%	14431
2023 Q4	–	Sell	-10	Closed	-$188	–	14333
2023 Q3	$188	Sell	10 -115	-92%	-$2.26K	﹤0.01%	14136
2023 Q2	$2.83K	Sell	125 -1,615	-93%	-$38K	﹤0.01%	13746
2023 Q1	$44.2K	Buy	+1,740	New	+$49.4K	﹤0.01%	12324

Citadel Advisors's CDTX Position: Q1 2026 in Review

Citadel Advisors sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 269,389 shares — an estimated $59.5M sold.

Citadel Advisors first reported a position in CDTX in Q2 2015 and held it in 17 quarters. The position peaked at $59.5M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Citadel Advisors reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 269,389 Cidara Therapeutics shares in Q1 2026, an estimated $59.5M.
Citadel Advisors first reported a position in Cidara Therapeutics in Q2 2015 and held it in 17 quarters.
Citadel Advisors's Cidara Therapeutics position peaked at $59.5M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.